Indian J Pharm Close
 

Figure 3: Forest plots of hazard ratios comparing progression-free survival with or without onartuzumab in intention-to-treat population (a) and MET-positive population (b). Funnel plots for publication bias in intention-to-treat population (c) and MET-positive population (d)

Figure 3:  Forest plots of hazard ratios comparing progression-free survival with or without onartuzumab in intention-to-treat population (a) and MET-positive population (b). Funnel plots for publication bias in intention-to-treat population (c) and MET-positive population (d)